CareDx (CDNA) director awarded 27,453 RSUs, 3-year vest
CareDx (CDNA) reported a director equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CareDx (CDNA) reported a director equity award. On 10/22/2025, the reporting person acquired 27,453 shares of Common Stock, labeled as an acquisition at a price of $0.
The award is represented by restricted stock units (RSUs) that vest in equal annual installments, with 100% vested on the third anniversary of October 22, 2025, subject to continued service. Each RSU represents the right to receive 1 share of Common Stock upon settlement for no consideration. Following the reported transaction, the reporting person beneficially owned 27,453 shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 27,453 | $0.00 | $0.00 |
Footnotes (2)
- F1. The reported securities are represented by restricted stock units ("RSUs"), which vest in equal annual installments, such that one-hundred percent of the RSUs will be vested on the third anniversary of October 22, 2025, subject to the Reporting Person's continuous service on each applicable vesting date.
- F2. Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CareDx (CDNA) disclose in this Form 4?
What is the vesting schedule for the CareDx RSUs?
What does each RSU represent in the CareDx transaction?
What is the role of the reporting person at CareDx (CDNA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.